<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10065">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096705</url>
  </required_header>
  <id_info>
    <org_study_id>MB102-137</org_study_id>
    <nct_id>NCT02096705</nct_id>
  </id_info>
  <brief_title>Phase III Insulin Add-On Asia Regional Program - ST</brief_title>
  <official_title>A 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate Efficacy and Safety of Dapagliflozin Added to Therapy of Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Singapore: Clinical Trials &amp; Epidemiology Research Unit (CTERU)</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to determine if after  24 weeks of oral daily administration, there will be a
      greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with
      Dapagliflozin 10 mg plus insulin compared to placebo plus insulin in subjects with type 2
      diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in HbA1c at Week 24</measure>
    <time_frame>Baseline (Day 1) and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Fasting plasma glucose (FPG) at Week 24</measure>
    <time_frame>Baseline (Day 1) and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body weight at Week 24</measure>
    <time_frame>Baseline (Day 1) and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Absolute calculated mean total daily dose of insulin (TDDI) at Week 24</measure>
    <time_frame>Baseline (Day 1) and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Group 1: Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Dapagliflozin Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <arm_group_label>Group 1: Dapagliflozin</arm_group_label>
    <other_name>BMS-512148</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin Placebo</intervention_name>
    <arm_group_label>Group 2: Dapagliflozin Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Subjects must have type 2 diabetes with inadequate glycemic control, defined as HbA1c
             ≥ 7.5% and ≤ 11.0% obtained at screening visit

          -  Subjects must be taking a stable mean dose of ≥ 20 IU injectable insulin daily for at
             least 8 weeks prior to enrollment

          -  Fasting C-peptide ≥ 1.0 ng/mL (0.34nmol/L) at enrollment visit

        Exclusion Criteria:

          -  Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of
             Enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
